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Abstract
Background: The current methods of assessing motor function rely primarily on the clinician’s judgment of the
patient’s physical examination and the patient’s self-administered surveys. Recently, computerized handgrip tools
have been designed as an objective method to quantify upper-extremity motor function. This pilot study explores the
use of the MediSens handgrip as a potential clinical tool for objectively assessing the motor function of the hand.
Methods: Eleven patients with cervical spondylotic myelopathy (CSM) were followed for three months. Eighteen
age-matched healthy participants were followed for two months. The neuromotor function and the patient-perceived
motor function of these patients were assessed with the MediSens device and the Oswestry Disability Index
respectively. The MediSens device utilized a target tracking test to investigate the neuromotor capacity of the
participants. The mean absolute error (MAE) between the target curve and the curve tracing achieved by the
participants was used as the assessment metric. The patients’ adjusted MediSens MAE scores were then compared to
the controls. The CSM patients were further classified as either “functional” or “nonfunctional” in order to validate the
system’s responsiveness. Finally, the correlation between the MediSens MAE score and the ODI score was investigated.
Results: The control participants had lower MediSens MAE scores of 8.09%± 1.60%, while the cervical spinal disorder
patients had greater MediSens MAE scores of 11.24% ± 6.29%. Following surgery, the functional CSM patients had an
average MediSens MAE score of 7.13% ± 1.60%, while the nonfunctional CSM patients had an average score of
12.41% ± 6.32%. The MediSens MAE and the ODI scores showed a statistically significant correlation (r = −0.341,
p < 1.14 × 10−5). A Bland-Altman plot was then used to validate the agreement between the two scores.
Furthermore, the percentage improvement of the the two scores after receiving the surgical intervention showed a
significant correlation (r = −0.723, p < 0.04).
Conclusions: The MediSens handgrip device is capable of identifying patients with impaired motor function of the
hand. The MediSens handgrip scores correlate with the ODI scores and may serve as an objective alternative for
assessing motor function of the hand.
Keywords: Cervical spondylosis, Handgrip, Motor deficit, Oswestry disability index
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Introduction
Cervical spondylotic myelopathy (CSM) is an age-related
form of spinal degeneration. It is the most common cause
of spinal pathology in patients over the age of 50 [1-3].
Most individuals with CSM have radiographic evidence
of cervical spine degenerative changes by the age of 30.
The incidence of CSM increases until the age of 60 [4,5].
As the elderly population grows, CSM is expected to
become an increasingly common problem facing patients
and the healthcare system [6,7]. CSM is known to impair
the neuromotor function of the hand, thus impairing the
performance of many daily activities. CSM can cause the
impairment of both the upper and lower extremities. The
symptoms commonly include motor weakness, pain, and
numbness. Consequently, CSM can have a serious impact
on the quality of life of the elderly population. For this
reason, timely diagnosis is critical [5-7].
The current methods for the clinical evaluation for
neuromotor deficits rely on scoring observable changes
in neuromuscular function [2,8]. These physical exam
maneuvers include the Barre test, the Hoffmann test, the
pronator drift test, the hand withdrawal reflex, and the
deep tendon reflexes [9,10]. The American Spinal Injury
Association (ASIA) motor score is another method of
determining the neuromotor function of patients, as it
assesses the strength of selected muscles against resis-
tance. Unfortunately, the aforementioned physical exam
maneuvers are limited by physician bias and by the subjec-
tive nature of their scoring systems [2,11]. Furthermore,
the negative predictive value (the number of patients who
have a negative test result that is consistent with a negative
history of a given diagnosis) of these tests is low, mak-
ing it difficult to rule out neuromotor deficits based solely
on these methods [11]. Radiographic imaging combined
with clinical exam findings have become the standard
of care in diagnosing spinal cord pathology. However,
radiographic imaging is expensive and often does not
correlate with functional impairment. Other scoring sys-
tems based on activities of daily living have become
widely used in assessing CSM patients. These scoring
systems include the Japanese-Orthopaedic-Association-
Score (JOA-Score) [12] and the Oswestry Disability Index
(ODI) [13]. However, these methods are not sensitive
to small changes in neuromotor function [14]. Some of
these methods, furthermore, are known to be affected by
response shift, which represents a change in the standard
of perceived health-related quality of life after receiving
medical treatment [15].
Systems that objectively measure neuromuscular func-
tion, such as the MediSens system, have gained popu-
larity for assessing neurodegenerative disorders [11,16].
These systems require the patient to perform “tracking
maneuvers” by varying their handgrip strength to follow
a target curve on a computer. The goal of the test is to
minimize the error between the target and the patient’s
tracking response. Handgrip motor function tests were
performed in stroke and Parkinson’s disease (PD) patients
as a method of assessing their function before and after
physical rehabilitation [17-19]. Recent studies have iden-
tified the sinusoidal curve tracking test as the most useful
tracking performance test for patients with neurodegen-
erative disorders [20]. Studies specific to the sinusoidal
curve have also demonstrated its ability to detect perfor-
mance deficits in the unaffected side of hemi-paraplegic
patients when compared to their healthy counterparts
[21,22]. To the best of our knowledge, handgrip tracking
devices have not been used to compare the preoperative
and the postoperative handgrip performance in patients
with CSM.
In this paper, we introduce the MediSens handgrip
device as an objective test to assess the neuromotor func-
tion. We validate its clinical usefulness by examining the
ability of the device in quantifying the neuromotor levels
of CSM patients and healthy participants, by examining
the capacity of the MediSens handgrip to track changes in
hand performance of CSM patients after receiving cervi-
cal decompression surgery (i.e., system’s responsiveness),
and by investigating its correlation to the patients’ per-
ceived motor deficits in performing daily activities (i.e.,
the ODI).
Materials andmethods
Participants
Eleven adult research participants who were scheduled
for elective cervical decompression surgery by DCL at the
UCLA Spine Center were recruited for this study. The
inclusion criteria included age (19-89 years old) and no
prior history of cervical pathology and/or neuromuscular
impairments. The mean age of the eleven study partic-
ipants was 58 (39-86). The mean age of the eighteen
control subjects was 63 (45-85). Informed consent was
obtained from all participants. Amedical chart reviewwas
performed and all eleven patients were noted to have doc-
umented symptoms of myelopathy manifested by upper
extremity paresthesia and radiculopathy. A review of pre-
operative imaging was performed which demonstrated
radiographic evidence of cervical spondylotic disease,
including spinal canal stenosis, osteophytic disease, facet
arthropathy, and ligamentous hypertrophy. This study was
reviewed and approved by the UCLA Institutional Review
Board.
MediSens handgrip device
Each participant was assessed for neuromotor function
of the clinically affected hand with the MediSens sys-
tem. This handgrip device delivers sensory information
to a computer which enables visualization of the patient’s
handgrip performance and collects sensory input data.
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The MediSens handgrip device in Figure 1 has three
components: the handle, the springs, and a displacement
sensor. The main body is composed of three rods and
a bottom compartment. The handle is connected to the
main body by three springs. These springs create resis-
tance to grasping motions. Five different springs with
the following spring constants were used to calibrate the
MediSens device with the patient’s hand grip strength: S1
(0.38 lbs/inch), S2 (0.88 lbs/inch), S3 (1.94 lbs/inch), S4
(5.10 lbs/inch), and S5 (10.70 lbs/inch).
Test administrators were not blind to the treatment
group. As an attempt to maintain continuity with the
patient and to reduce performance variability due to
changes in test administrators, each test administrator
was responsible for testing the same study participants.
Testing methods were the same for both the control and
the treatment groups.
Testing procedure
In order to calibrate the MediSens handgrip device with
the subjects’ grip strength, a set of three springs were cho-
sen to provide resistance equal to 70-80% of the subject’s
maximum voluntary contraction (MVC). The tracking
tests, as shown in Figure 2, were normalized to the indi-
vidual’s MVC such that the maximum magnitude of the
tracking target is equal to the measured MVC.
The sinusoidal target moved towards the left of the
screen at a constant speed. The dotted circle in Figure 2
moved in the y-axis according to the grip force exerted
by the subject. The software also displayed the history
of the subject’s performance. The objective of the test
was to minimize the errors between the target wave-
form and the dotted circle. At every clinical visit, par-
ticipants performed three 45-second tracking tests. The
Figure 1 The MediSens handgrip device used in this work, which
has also been introduced in [23].
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Figure 2 Example illustration of the target tracking test used in
the MediSens system [23].
three MediSens mean absolute error (MAE) scores from
a given test date were averaged to represent the overall
performance for that clinical visit.
Longitudinal tracking of the patients’ hand motor func-
tion was performed an hour prior to surgery and again
at 24 hours, 48 hours, 2 weeks, and 3 months postop-
eratively. However, only the preoperative and 3-month
postoperative data points were used in this study, due to
the results of previous studies that did not demonstrate
significant improvement in neuromotor function until 3-
4 months postoperatively [15]. During the postoperative
period, patients were given a cervical collar and were
prescribed hand physical therapy as needed. Testing for
controls was conducted at 0 weeks, 2-3 weeks and 4-6
weeks.
Analysis
The MediSens MAE score was used to quantify motor
function. It was calculated by averaging the distance
between the target curve and the curve tracing achieved
by a patient. The sinusoidal test was normalized to the
MVC of the subject. Thus, the unit of the MediSens MAE
score is % MVC.
In order to track the change in motor function sec-
ondary to surgical intervention, a percentage improve-
ment (% Improvement) of the MediSens MAE score was
computed using (MAEpost − MAEpre)/MAEpre.
ODI surveys
The ODI survey consists of ten questions regarding the
patient’s ability to perform the activities of daily liv-
ing [24,25]. The answer choices describe a progressively
increasing level of neuromotor impairment that corre-
lates with a higher numeric score. The scores on the 10
questions were averaged to create a numeric value that
indicates the patient’s perceived level of motor function.
ODI scores were collected from CSM patients preoper-
atively and at three months postoperatively. Patients with
a three month postoperative ODI score ≤ 0.6 were cate-
gorized as “functional”, while patients with three month
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postoperative ODI score > 0.6 were categorized as “non-
functional” [13]. This threshold-based categorization is an
approximated representation of a patient group (i.e., ≤
0.6) that is relatively functional in performing daily activ-
ities compared to the rest of the patients (i.e., > 0.6)
[13].
Written informed consent was obtained from all
patients for publication of this study. A copy of the written
consents are available for review by the Editor-in-Chief of
this journal.
The study was performed in accordance with the Dec-
laration of Helsinki, the protocol was approved by the
Human Research Protection Program at UCLA and all
patients or their carers gave informed consent. This
research was approved by the University of California, Los
Angeles, Institutional Review Board (IRB #: 12-000009-
CR-00002).
Results
Table 1 describes the demographics of the current study.
18 control participants and 11 surgical patients were
enrolled, with mean ages of 63 and 58 years respectively.
The MediSens MAE scores of CSM patients and control
subjects
Each participant performed the tracking test three times
per clinical visit. The average MediSens MAE score of the
three tests was used to quantify the hand neuromuscular
function for that test date. Table 2 summarizes the aver-
age scores of the control participants at 0 weeks and at the
two-month mark. It also summarizes the average MediS-
ens MAE scores of the CSM patients preoperatively and
at three months postoperatively. The table further reports
the average MediSens MAE scores of the postoperative
CSM patients divided into functional or nonfunctional
groups as described in Section ‘ODI surveys’.
The averageMediSensMAE score for the control partic-
ipants was 8.09± 1.60 at week 0 and was 6.21± 1.51 at the
two-month follow-up. For the CSM patients, the preop-
erative and the three months postoperative tests revealed
average MediSens MAE scores of 11.24 ± 6.29 and
8.71 ± 4.17 respectively. The CSM patients were catego-
Table 1 Demographic information about the participants
Control (n = 18) CSM Patients (n = 11)
Age range 45-85 39-86
Mean age 63 ± 3.38 58 ± 3.20
Mean weight 149 ± 7.93 166 ± 9.84
Mean gender 33% 63%
Cervical neck injury - 1 (9%)
Cervical neck degenerative - 10 (91%)
symptoms
Table 2 A summary of theMediSens MAE scores of control
subjects and CSM patients
MeanMediSens MAE± SD
Control
First Test 8.09 ± 1.60
Last Test 6.21 ± 1.51
CSM Patients
Preoperative test 11.24 ± 6.29
3 month postoperative 8.71 ± 4.17
test (aggregate)
3 month postoperative 7.13 ± 1.60
test (functional group)
3 month postoperative 12.41 ± 6.32
test (nonfunctional group)
rized into functional and nonfunctional groups based
on the assessment method of Fairbanks et al. [13]. The
functional group demonstrated a postoperative MediSens
MAE score of 7.13 ± 1.60, while the nonfunctional group
showed a score of 12.41 ± 6.32.
The percentage change between the first and the last
test sessions was quantified to further demonstrate the
change in handgrip performance. Control participants
improved 17% ± 15% after two months. This demon-
strates a general pattern of motor learning. In con-
trast, CSM patients improved 21% ± 27% during the
three months following surgery. This shows that the
motor function of CSM patients improved more than the
expected motor learning. This finding suggests a bene-
fit to surgical intervention. Interestingly, in Table 3, the
functional group improved by 30% ± 18%, while non-
functional group members declined in performance by
11% ± 25%. Possible causes for the discrepancy in perfor-
mance between the functional and nonfunctional groups
are explored in the discussion.
Correlation to existing methods
The ODI surveys were administered at each MediSens
handgrip testing and compared to the MediSens MAE
scores. This tested our hypothesis that there exists a cor-
relation between ODI scores and handgrip performance.
It also tested our hypothesis that a postoperative improve-
ment in ODI correlates with an objective improvement
in handgrip neuromuscular function as demonstrated
Table 3 Percentage change in theMediSens MAE score
between initial and final time points
% Improvement T-test vs.
MediSens MAE control
Control 17% ± 15% -
CSM Patients - Aggregated 21% ± 27% p < 0.88
CSM Patients - Functional 30% ± 18% p < 0.09
CSM Patients - Nonfunctional −11% ± 25% p < 0.16
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by the MediSens device. The Pearson product-moment
correlation coefficient (or Pearson’s r) was used to quan-
tify the level of correlation [26-28]. Figure 3(a) demon-
strates the pre and postoperative correlation between
the MediSens MAE and the ODI scores of the surgi-
cal patients (r = 0.0025, p < 0.00806). The Cook’s
distance (di) of each point was used to identify any pos-
sible outliers, which was calculated using the following
equation:
di =
∑n
j=1
( ˆMAEj − ˆMAEj−i
)2
(k + 1)s2 , i = 1, . . . , n.
where n is the total number of data points, ˆMAEj repre-
sents the regression estimate of the MediSens MAE score
at point j, and ˆMAEj−i represents the regression estimate
of the MediSens MAE score at point j when the data point
i is removed. Furthermore, s represents the estimated root
mean square error. A data point is labeled as an outlier if
di ≥ 4n−(k+1) where k is the number of fitted parameters in
our linear model (i.e., k = 1). As a consequence, one data
point, which is labeled in Figure 3(a), has been verified as
an outlier. Figure 3(b) represents the correlation between
the MediSens MAE and ODI scores when the outlier is
removed. Both the r and p-value have been significantly
improved (r = −0.341, p < 1.14 × 10−5). A Bland-
Altman plot was constructed in order to verify the agree-
ment between the MediSens MAE and the ODI scores
as shown in Figure 4. The mean difference was −0.26
(95% C.I. of −0.36 and −0.15), the upper limit of
agreement was 0.22, and the lower limit of agreement
was −0.73. Percentage improvement in the ODI scores
also displayed a strong correlation to the percentage
improvement in the MediSens MAE scores as shown in
Figure 3(c) (r = −0.553, p < 0.0300). The predefined out-
lier was removed and the result is illustrated in Figure 3(d).
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Figure 3 Various correlation results between the ODI and the MediSens MAE scores. (a) Correlation between the ODI and the MediSens MAE
scores, (b) Correlation between the ODI and the MediSens MAE scores with the outlier removed, (c) Correlation between % Improvement of the
ODI and the MediSens MAE scores, (d) Correlation between % Improvement of the ODI and the MediSens MAE scores with the outlier removed.
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Figure 4 Bland-Altman plot between the ODI and the MediSens
MAE scores. The x-axis represents the average value of the two
scores and the y-axis represents the difference of the two scores.
The correlation coefficient was significantly improved to
r = −0.723, p < 0.0402. These results are also summa-
rized in Table 4.
Discussion
Method of quantifying MediSens handgrip performance
The MediSens MAE scores demonstrated a significant
difference between the control participants and the pre-
operative CSM patients. Table 2 shows that the control
participants had an average MediSens MAE score of
8.09± 1.60 at the initial attempt, whereas the preoperative
CSM patients had an average score 11.24± 6.29. This data
suggests that, on average, the control participants initially
made fewer errors during tracking tests compared to the
CSM patients. Furthermore, the variance in the MediSens
MAE scores was significantly lower in the control subjects
(1.60) than the CSM patients (6.29). This large variability
in the baseline MediSens MAE scores is consistent with
reports by Manion et al., who demonstrated the presence
of high variability in the baseline ODI scores between the
control and the patients [25].
Table 2 and Figure 5 show that CSM patients’ aver-
age MediSens MAE scores improved to 8.71 ± 4.17 after
surgery. The patients were further categorized into the
Table 4 Correlation between the ODI and theMediSens
MAE scores
r p-value
MediSens MAE vs. ODI (with outlier) 0.00250 0.008
MediSens MAE vs. ODI (without outlier) −0.341 1.14 × 10−5
% Improvement MediSens MAE vs. ODI −0.553 0.03
(with outlier)
% Improvement MediSens MAE vs. ODI −0.723 0.04
(without outlier)
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Figure 5 The averageMediSensMAE scores at the initial test date
and the final test date were computed for control participants
and CSMpatients. Based on final ODI assessment, CSM patients were
separated into functional and nonfunctional groups, namely patients
who improved after surgery and patients who did not improve after
surgery. The preoperative and postoperative MediSens MAE scores
were also compared for these functional and nonfunctional groups.
functional and nonfunctional groups according to their
postoperative ODI scores, as discussed in Section ‘ODI
surveys’. The functional group demonstrated superior
postoperative handgrip performance and less variability
in the average MediSens MAE score (7.13 ± 1.60), com-
pared to the nonfunctional group (12.41 ± 6.32). After
further reviewing the past medical history of patients in
the nonfunctional group, several factors were noted to be
contributing to their lack of postoperative improvement.
These factors included non-compliance with postopera-
tive exercise restrictions and thrombophlebitis.
Patient progress assessment with MediSens data
The MediSens handgrip tracking tests were performed
preoperatively and the patients were followed for three
months postoperatively. The patients were expected to
improve their MediSens MAE scores during this time
period secondary to motor learning. This is apparent in
Table 2 and Figure 6, where both the control group and the
surgical group improved in their average MediSens MAE
scores throughout the course of the study.
Unfortunately, motor learning is an unavoidable con-
founding factor in tracking tests. We confirmed this
learning effect in healthy subjects, which resulted in
a slight improvement in the MediSens MAE score (p-
value < 0.0002) as summarized in Table 2. The aver-
aged MediSens MAE scores at the initial and the two-
month attempts for the control group were 8.09 ± 1.60
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Figure 6 Percent change in the MediSens MAE scores revealed
motor improvement in both the control and pooled
experimental groups. Functional and nonfunctional groups are
separated as previously described.
and 6.21 ± 1.51 respectively. This data was used to
account for the learning effect in the surgical group. The
functional patients had a preoperative average MediSens
MAE score of 11.46 ± 6.99 and a postoperative score of
7.13 ± 1.60, which showed a near-significant improve-
ment (p-value < 0.0640). The nonfunctional patients
had a preoperative averaged MediSens MAE score of
11.24 ± 6.29 and a postoperative score of 12.41 ± 6.32,
which showed no improvement (p-value < 0.94). As illus-
trated in Figure 6, these results demonstrate that both the
control and the functional patient population had some
degree of improvement in their hand neuromotor perfor-
mance when compared to the nonfunctional patients.
In Table 3, the percentage improvement of control par-
ticipants was 17% ± 15%, whereas the functional group
had an average percent improvement of 30% ± 18%. The
13% increase in improvement of the functional group,
although not statistically significant (p-value < 0.0834),
suggests that the patients’ improvement was not due to the
effects of learning alone. It suggests that their improve-
ment in baseline motor function was the result of the
surgical intervention.
In summary, the MediSens handgrip was able to differ-
entiate between the expectedmotor learning and the post-
operative improvement in handgrip neuromotor function
of CSM patients. This suggests that it can be used to
objectively quantify different levels of hand neuromotor
function and to track postoperative rehabilitation.
Correlation between subjective and objective data
Investigating the correlation of a new measurement to
other existingmeasurements is a commonmethod for val-
idating the reliability and consistency of a new tool [13].
Here, we compared the improvement in handgrip per-
formance (i.e., the MediSens MAE scores) with patients’
perceived levels of motor deficits in performing daily
activities (the ODI scores). The Pearson product-moment
correlation coefficient (or Pearson’s r) was used to quan-
tify the level of correlation [26-28].
Table 4 and Figure 3(b) shows that the ODI and the
MediSensMAE scores had a statistically significant corre-
lation (r = −0.341, p < 1.14 × 10−5). The Bland-Altman
plot was used to assess the agreement between theMediS-
ens MAE and ODI scores. The mean difference (i.e., the
bias) was −0.26 (95% C.I. of −0.36 and −0.15) with an
upper limit of agreement of 0.22 and a lower limit of
agreement of −0.73. The plot showed a strong positive
correlation between the mean and the difference of the
two measures. This pattern is due to a variation in the
ranges of the MediSens MAE and the ODI scores. That is,
theMediSensMAE scores ranged from 0.049 to 0.28 while
the ODI scores ranged from 0.21 to 0.94. This small range
of the MediSens MAE and large range of the ODI scores
accounts for the increasing differences as the averages
get larger. However, the results are uniformly distributed
within the limits of agreement, which indicates that there
exists a considerable degree of agreement between the two
scores.
Another means of comparing the MediSens MAE score
with the ODI score is to correlate the percentage improve-
ment of the two scores after receiving medical interven-
tion. Table 4 and Figure 3(d) show that the percentage
improvement in the MediSens MAE and the ODI scores
had a significant correlation (r = −0.723, p < 0.04).
Although the MediSens MAE score only quantifies
hand neuromotor function, these findings demonstrate
the potential use of tracking handgrip progress to help
interpret and to complement surveys, like the ODI, that
assess global neuromotor function.
Subjective and objective tests for neuromotor assessment
We have demonstrated the ability of the MediSens hand-
grip to track patients’ postoperative hand rehabilitation.
Tracking patient progress using patient-reported out-
comes (e.g., the ODI) is difficult because of its subjective
nature. Complications with the use of a subjective test
to assess patient rehabilitation include misinterpretation
of a survey question, adjusting responses to reflect a
personal belief system, and offering biased responses to
prevent “regret or self-blame” for undergoing surgery [25].
More recently, the phenomenon of “response shift” has
offered further insight into the issues with tracking patient
progress through patient-reported outcomes like the ODI
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[29]. Response shift refers to a changes in patients’ per-
sonal standards, priorities, and concepts toward healthy-
related quality of life as a result of medical intervention
[29]. Furthermore, Trachter’s study shows carpal tunnel
syndrome that the patients’ reports of functional capacity
were lower than the anticipated capacity [30,31]. Fairbank
et al. implicated “inconsistencies in answering questions
[and] the natural fluctuations of symptoms as well as clin-
ical improvements” as sources of errors [13]. Lastly, the
use of changes in the averaged ODI scores for large-scale
studies may overshadow inconsistencies in individual ODI
results [25]. Such variability inODI scores is implicit in the
survey’s subjective nature and becomes problematic when
assessing the patients’ motor progress [29]. Previous stud-
ies have demonstrated the usefulness of the ODI scores
for assessing motor function, but more objective clinical
tests are needed for tracking changes in motor func-
tion over time [13,32,33]. Objective testing instruments,
such as the MediSens handgrip, may be a more accurate
representation of an individual’s motor capacity because
they eliminate the chances of subjective responses to
questions.
Because this project was a pilot study, we encountered
some difficulties. Our sample size created a difference
in the male-to-female ratio between control and CSM
patient groups, and it has underestimated the statisti-
cal power of the correlation between the MediSens MAE
and the ODI scores. Despite the difference in the ratio of
male to female, we have not found any statistically sig-
nificant difference in the MediSens MAE scores within
the demographic of control participants; there was no sta-
tistically significant difference between male and female
participants (p-value < 0.129), between weights at <
160 pounds and at ≥ 160 pounds (p-value < 0.318),
nor among all different permutations of age groups: 40s ,
50s, 60s, and 70+. This reflects the efficacy of calibrating
handgrip strength and that these demographics mark-
ers have not confounded the MediSens handgrip results.
We acknowledge the limitation of a small sample size.
However, this pilot study introduces the potential for a
novel, objective, and quantitative test for assessing clinical
progress of CSM patients. We hope this study will encour-
age research for elucidating other objective methods for
assessing global neuromotor function.
Conclusions
In this paper, we introduce theMediSens system as a novel
instrument to identify neuromotor deficits. Our data sug-
gests that the MediSens handgrip device can differentiate
between normal motor learning and the postoperative
neuromotor improvement in CSM patients. The MediS-
ens handgrip scores may be used to supplement or replace
the ODI surveys in CSM patients with hand neuromotor
deficits.
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